Aerobic Exercise on Platelet Mitochondrial Function

March 20, 2025 updated by: Jong-Shyan Wang, Chang Gung Memorial Hospital

The Effects of Aerobic Exercise on Aerobic Fitness and Platelet Mitochondrial Bioenergetics

This study explores how exercise affects blood platelets and their role in clotting. Regular exercise can influence how efficiently clots form in the body. Intense exercise tends to increase platelet activity and the expression of certain molecules on their surface, while moderate exercise can decrease this activity. Since platelets are responsible for blood clotting, understanding how they function can be crucial.

Understanding Platelets:

Platelets are blood cells that help in clotting. The mitochondria within platelets help regulate their function. If these mitochondria don't work properly, it can lead to issues with clotting. By examining how exercise changes platelet mitochondria, the investigators can potentially identify important markers for health and disease progression.

Study Design:

This study compares two types of exercise routines: circuit training and stationary bicycle training.

Participants will be randomly assigned to one of the two groups:

Circuit Training Group: This involves moving through different exercise stations within a set time, targeting various body parts. It's tailored for those who might find regular exercise challenging, helping to reduce fatigue in any single area and improve overall fitness.

Bicycle Training Group: This involves exercising on a stationary bike. Both exercise groups will engage in high-intensity interval training for about 40 minutes, five times a week, over six weeks.

Assessment: Participants will undergo tests to measure endurance and physical function.

Blood Sampling: Blood will be drawn before and after the exercise tests, with 20 milliliters taken from the arm vein. Blood samples will also be collected at the start and end of a 6-week intervention, totaling 80 milliliters throughout the study. This helps the investigators analyze how platelets are affected by exercise.

This study is designed to help the investigators better understand how different types of exercise can benefit platelet function and overall health. Participanting in this research could contribute to the knowledge about how could exercise influence blood clotting and related health conditions. Participants' involvement will include exercise routines or maintaining your current lifestyle, along with simple blood tests. Participation is highly valuable and can help pave the way for new health insights and treatments.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taoyuan, Taiwan, 333
        • Chang Gung University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Willing to sign a written informed consent form.
  • Ages 18 to 28.
  • No regular exercise habit (defined as exercising 2 times a week or less, for 60 minutes or less each time, for over a year).

Exclusion Criteria:

  • Overweight (BMI > 24) or underweight (BMI < 19).
  • Smoked within the past year, or consumed alcohol in the past month exceeding 60 grams of alcohol per occasion.
  • Having metabolic, circulatory, respiratory, or immune-related diseases or risk factors such as diabetes, hyperlipidemia, hypertension, heart disease, clotting disorders, asthma, allergies, autoimmune diseases, etc.
  • Long-term use of any nutritional supplements or medications (e.g., vitamins, pain relievers, aspirin, traditional Chinese medicine).
  • Significant knee injuries within the past year (e.g., ligament damage, fractures).
  • Students and laboratory staff taught, assessed, evaluated, tested, or appraised by the principal investigator of this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Circuit training group
Other: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Participants in the exercise groups were trained five times a week for six weeks. The regimen began with a 5-min warm-up and ended with a 5-min cool-down, both at 40% of heart rate reserved (HRR). The circuit training participants were trained for three bouts of 10-min moderate-intensity exercise (60% of HRR) with 1-min rest intervals at a stationary ergometer, a rowing machine, and an elliptical trainer, respectively. The cycling training group was trained on an ergometer for three bouts of 10-min cycling on a stationary ergometer.
Active Comparator: Cycle ergometer group
Other: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Participants in the exercise groups were trained five times a week for six weeks. The regimen began with a 5-min warm-up and ended with a 5-min cool-down, both at 40% of heart rate reserved (HRR). The circuit training participants were trained for three bouts of 10-min moderate-intensity exercise (60% of HRR) with 1-min rest intervals at a stationary ergometer, a rowing machine, and an elliptical trainer, respectively. The cycling training group was trained on an ergometer for three bouts of 10-min cycling on a stationary ergometer.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Platelet mitochondrial respiration
Time Frame: baseline and 2 days upon the completion of the 6-week intervention
The mitochondrial OXPHOS and ET capacities in platelets were analyzed.
baseline and 2 days upon the completion of the 6-week intervention
Cardiopulmonary fitness
Time Frame: baseline and 2 days upon the completion of the 6-week intervention
Graded Exercise Test was performed on an ergometer.
baseline and 2 days upon the completion of the 6-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Chang Gung Memorial Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 31, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 31, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 19, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 20, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 27, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 27, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 20, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 202300538B0

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings